Nuvalent Inc.

70.97
-2.08 (-2.85%)
At close: Mar 31, 2025, 3:59 PM
70.92
-0.07%
After-hours: Mar 31, 2025, 04:40 PM EDT
-2.85%
Bid 67.13
Market Cap 5.08B
Revenue (ttm) n/a
Net Income (ttm) -262.37M
EPS (ttm) -3.93
PE Ratio (ttm) -18.06
Forward PE -19.46
Analyst Buy
Ask 74.76
Volume 725,478
Avg. Volume (20D) 507,059
Open 72.42
Previous Close 73.05
Day's Range 67.61 - 72.39
52-Week Range 61.80 - 113.51
Beta 1.42

About NUVL

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 29, 2021
Employees 142
Stock Exchange NASDAQ
Ticker Symbol NUVL
Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for NUVL stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 55.00% from the latest price.

Stock Forecasts
6 months ago
-6.61%
Nuvalent shares are trading lower after the compan... Unlock content with Pro Subscription
6 months ago
+28.27%
Nuvalent shares are trading higher after the company highlighted results for its ROS1 and ALK-Positive NSCLC programs and accelerated its development timeline. Also, the company announced a $350 million public offering and multiple firms raised their respective price targets on the stock.